Eylea Alternatives Compared
| Eylea | Byooviz | Lucentis |
|
|---|
| Eylea (aflibercept) | Byooviz (ranibizumab) | Lucentis (ranibizumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Eylea is a VEGF (vascular endothelial growth factor) inhibitor that is used to treat a variety of eye conditions that may affect your vision, such as macular degeneration, diabetic retinopathy (DR)... View more |
Prescription only
Prescribed for Macular Degeneration, Macular Edema, Myopic Choroidal Neovascularization. Byooviz may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Diabetic Macular Edema, Macular Degeneration, Macular Edema, Myopic Choroidal Neovascularization, Diabetic Retinopathy. Lucentis may also be used for purposes not listed in this... View more |
Related suggestions Macular Degeneration
Macular Edema
Popular comparisons
|
|||||||||||||||||||||||
| More about Eylea (aflibercept) | More about Byooviz (ranibizumab) | More about Lucentis (ranibizumab) | ||||||||||||||||||||||||
| Generic Status | ||||||||||||||||||||||||||
|
No lower-cost generic available |
No lower-cost generic available |
No lower-cost generic available |
||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Eylea has an average rating of 6.5 out of 10 from a total of 41 ratings on Drugs.com. 59% of reviewers reported a positive effect, while 30% reported a negative effect. |
Be the first to share your experience with this drug. |
Lucentis has an average rating of 7.0 out of 10 from a total of 13 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 17% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
|
See also: Eylea side effects in more detail. |
See also: Byooviz side effects in more detail. |
Common side effects include:
See also: Lucentis side effects in more detail. |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Eylea prices |
View all Byooviz prices |
View all Lucentis prices |
||||||||||||||||||||||||
| Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
Other ranibizumab brands include: Cimerli, Lucentis, Susvimo | Other ranibizumab brands include: Byooviz, Cimerli, Susvimo | ||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
144 hours |
216 hours |
216 hours |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
No known drug interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
A total of 1 drugs are known to interact with Byooviz:
|
A total of 1 drugs are known to interact with Lucentis:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.